Vaderis exits stealth as ex-Almac Discovery candidate enters clinical development

By Nick Taylor

- Last updated on GMT

(enjoynz/iStock via Getty Images Plus)
(enjoynz/iStock via Getty Images Plus)

Related tags: Almac, Almac Discovery, hematology, blood disorder, Clinical trials, Drug development

The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company

Vaderis Therapeutics has emerged from stealth with a clinical-phase treatment for a genetic blood vessel disorder that it licensed from Almac Discovery.

The drug candidate, VAD044, is a once-daily, orally administered, allosteric AKT inhibitor that Vaderis has taken into clinical development as a treatment for hereditary hemorrhagic telangiectasia, a condition in which malformations of blood vessels lead to outcomes including strokes and digestive tract bleeding.

Evidence that the PI3K/AKT/mTOR pathway is frequently mutated in cancers has led multiple research groups to develop AKT inhibitors. However, Almac found relatively few groups were working on allosteric inhibitors, which induce a conformational change to inhibit activation of the pathway.

Seeing allosteric inhibitors as a way to improve selectivity for AKT, and circumvent feedback mechanisms that are commonly observed following treatment with ATP competitive inhibitors, Almac Discovery got to work, as Alan Lamont, the company’s vice president of business development and licensing, explained.

When we first entered the AKT field, the vast majority of the AKT inhibitors in development were ATP competitive, thus we saw an opportunity to develop a best in class, subtype selective, allosteric AKT inhibitor for use in specific cancer indications. Once we had developed such an inhibitor, we were able to profile the compound in therapeutic indications beyond oncology where AKT played an important role, and this subsequently led to the collaboration with Vaderis​,” said Lamont.

Vaderis struck a licensing deal with Almac Discovery and raised around CHF18m ($18.4m) from Medicxi in 2020, leading to its recent emergence from stealth and initiation of a proof-of-concept clinical trial of VAD044.

The progress of VAD044 is built on the early work Almac Discovery did to identify and advance the drug candidate. Armed with the capabilities to initiate new discovery projects and take them up to candidate drug status, the biotech presented Vaderis with a molecule that was already in late-stage preclinical development.

We used a combination of high-throughput screening and knowledge-based design, based on published scaffolds, to identify VAD044. Structural biology was also used to understand and optimize binding modes, and enhance selectivity. To complement the internal capabilities and expertise that Almac Discovery has, we also utilize an extensive network of partners (e.g. CROs; academic collaborators; scientific, medical, and regulatory consultants) to advance novel assets​,” said Lamont.

Related news

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Related suppliers

Follow us

Products

View more

Webinars